nodes	percent_of_prediction	percent_of_DWPC	metapath
Everolimus—CYP3A4—Temozolomide—malignant glioma	0.197	1	CbGbCtD
Everolimus—Wound dehiscence—Carmustine—malignant glioma	0.0163	0.0511	CcSEcCtD
Everolimus—Alveolitis—Temozolomide—malignant glioma	0.0145	0.0454	CcSEcCtD
Everolimus—Wound—Carmustine—malignant glioma	0.013	0.0406	CcSEcCtD
Everolimus—Wound infection—Temozolomide—malignant glioma	0.0111	0.0347	CcSEcCtD
Everolimus—MTOR—blood vessel—malignant glioma	0.0103	0.145	CbGeAlD
Everolimus—Hemiparesis—Temozolomide—malignant glioma	0.00867	0.0271	CcSEcCtD
Everolimus—Disease progression—Carmustine—malignant glioma	0.00861	0.027	CcSEcCtD
Everolimus—Pulmonary toxicity—Carmustine—malignant glioma	0.00828	0.0259	CcSEcCtD
Everolimus—Sirolimus—FGF2—malignant glioma	0.00818	1	CrCbGaD
Everolimus—Fibrosis—Carmustine—malignant glioma	0.00658	0.0206	CcSEcCtD
Everolimus—MTOR—embryo—malignant glioma	0.00612	0.0864	CbGeAlD
Everolimus—Nephrotoxicity—Carmustine—malignant glioma	0.00591	0.0185	CcSEcCtD
Everolimus—MTOR—brainstem—malignant glioma	0.00561	0.0792	CbGeAlD
Everolimus—MTOR—retina—malignant glioma	0.00541	0.0764	CbGeAlD
Everolimus—MTOR—telencephalon—malignant glioma	0.00498	0.0703	CbGeAlD
Everolimus—FKBP1A—retina—malignant glioma	0.00487	0.0687	CbGeAlD
Everolimus—Opportunistic infection—Temozolomide—malignant glioma	0.00451	0.0141	CcSEcCtD
Everolimus—FKBP1A—telencephalon—malignant glioma	0.00448	0.0632	CbGeAlD
Everolimus—Impaired healing—Carmustine—malignant glioma	0.00435	0.0136	CcSEcCtD
Everolimus—Lung infiltration—Carmustine—malignant glioma	0.00401	0.0126	CcSEcCtD
Everolimus—Lymphopenia—Temozolomide—malignant glioma	0.00355	0.0111	CcSEcCtD
Everolimus—Azotaemia—Carmustine—malignant glioma	0.00353	0.011	CcSEcCtD
Everolimus—FKBP1A—medulla oblongata—malignant glioma	0.00352	0.0497	CbGeAlD
Everolimus—MTOR—spinal cord—malignant glioma	0.00349	0.0493	CbGeAlD
Everolimus—Nephropathy toxic—Carmustine—malignant glioma	0.00327	0.0102	CcSEcCtD
Everolimus—FKBP1A—midbrain—malignant glioma	0.00322	0.0454	CbGeAlD
Everolimus—FKBP1A—spinal cord—malignant glioma	0.00314	0.0443	CbGeAlD
Everolimus—Transaminases increased—Carmustine—malignant glioma	0.00309	0.00967	CcSEcCtD
Everolimus—Haemorrhoids—Temozolomide—malignant glioma	0.00309	0.00967	CcSEcCtD
Everolimus—Deep vein thrombosis—Temozolomide—malignant glioma	0.00299	0.00935	CcSEcCtD
Everolimus—Oral candidiasis—Carmustine—malignant glioma	0.00296	0.00926	CcSEcCtD
Everolimus—Oral candidiasis—Temozolomide—malignant glioma	0.00286	0.00895	CcSEcCtD
Everolimus—MTOR—central nervous system—malignant glioma	0.00283	0.04	CbGeAlD
Everolimus—Embolism—Temozolomide—malignant glioma	0.00283	0.00886	CcSEcCtD
Everolimus—MTOR—cerebellum—malignant glioma	0.00277	0.0391	CbGeAlD
Everolimus—Interstitial lung disease—Carmustine—malignant glioma	0.00266	0.00832	CcSEcCtD
Everolimus—Thrombosis—Carmustine—malignant glioma	0.00266	0.00832	CcSEcCtD
Everolimus—Interstitial lung disease—Temozolomide—malignant glioma	0.00257	0.00804	CcSEcCtD
Everolimus—FKBP1A—central nervous system—malignant glioma	0.00255	0.0359	CbGeAlD
Everolimus—FKBP1A—cerebellum—malignant glioma	0.00249	0.0351	CbGeAlD
Everolimus—Menorrhagia—Temozolomide—malignant glioma	0.00245	0.00768	CcSEcCtD
Everolimus—Vaginal haemorrhage—Temozolomide—malignant glioma	0.00245	0.00768	CcSEcCtD
Everolimus—Herpes zoster—Temozolomide—malignant glioma	0.00241	0.00755	CcSEcCtD
Everolimus—Otitis media—Temozolomide—malignant glioma	0.00233	0.00731	CcSEcCtD
Everolimus—Coagulopathy—Temozolomide—malignant glioma	0.00233	0.00731	CcSEcCtD
Everolimus—MTOR—brain—malignant glioma	0.00225	0.0317	CbGeAlD
Everolimus—Endocrine disorder—Temozolomide—malignant glioma	0.00219	0.00686	CcSEcCtD
Everolimus—Amenorrhoea—Temozolomide—malignant glioma	0.00207	0.00647	CcSEcCtD
Everolimus—FKBP1A—brain—malignant glioma	0.00202	0.0285	CbGeAlD
Everolimus—Viral infection—Temozolomide—malignant glioma	0.00201	0.0063	CcSEcCtD
Everolimus—Leukocytosis—Carmustine—malignant glioma	0.002	0.00626	CcSEcCtD
Everolimus—Hepatic enzyme increased—Temozolomide—malignant glioma	0.00192	0.00601	CcSEcCtD
Everolimus—Pulmonary embolism—Carmustine—malignant glioma	0.00188	0.00589	CcSEcCtD
Everolimus—Musculoskeletal pain—Temozolomide—malignant glioma	0.00184	0.00576	CcSEcCtD
Everolimus—Pulmonary embolism—Temozolomide—malignant glioma	0.00182	0.00569	CcSEcCtD
Everolimus—Phosphatase alkaline increased—Temozolomide—malignant glioma	0.00182	0.00569	CcSEcCtD
Everolimus—Skin exfoliation—Carmustine—malignant glioma	0.00179	0.00562	CcSEcCtD
Everolimus—Candida infection—Carmustine—malignant glioma	0.00179	0.00562	CcSEcCtD
Everolimus—Candida infection—Temozolomide—malignant glioma	0.00173	0.00543	CcSEcCtD
Everolimus—Skin exfoliation—Temozolomide—malignant glioma	0.00173	0.00543	CcSEcCtD
Everolimus—Neoplasm—Carmustine—malignant glioma	0.0017	0.00532	CcSEcCtD
Everolimus—Neoplasm—Temozolomide—malignant glioma	0.00164	0.00514	CcSEcCtD
Everolimus—Sepsis—Carmustine—malignant glioma	0.00163	0.00511	CcSEcCtD
Everolimus—Diabetes mellitus—Carmustine—malignant glioma	0.00157	0.00491	CcSEcCtD
Everolimus—Blood alkaline phosphatase increased—Temozolomide—malignant glioma	0.00152	0.00475	CcSEcCtD
Everolimus—Gastroenteritis—Temozolomide—malignant glioma	0.00149	0.00466	CcSEcCtD
Everolimus—Hepatic failure—Temozolomide—malignant glioma	0.00147	0.00459	CcSEcCtD
Everolimus—Nasal congestion—Temozolomide—malignant glioma	0.00145	0.00453	CcSEcCtD
Everolimus—Hot flush—Temozolomide—malignant glioma	0.00141	0.00441	CcSEcCtD
Everolimus—Menopausal symptoms—Temozolomide—malignant glioma	0.0014	0.00438	CcSEcCtD
Everolimus—Dermatitis exfoliative—Temozolomide—malignant glioma	0.0014	0.00438	CcSEcCtD
Everolimus—Hyponatraemia—Carmustine—malignant glioma	0.00137	0.00429	CcSEcCtD
Everolimus—Liver function test abnormal—Carmustine—malignant glioma	0.00126	0.00394	CcSEcCtD
Everolimus—Hypokalaemia—Carmustine—malignant glioma	0.00124	0.00389	CcSEcCtD
Everolimus—Dehydration—Temozolomide—malignant glioma	0.00123	0.00384	CcSEcCtD
Everolimus—Dry skin—Temozolomide—malignant glioma	0.00121	0.00378	CcSEcCtD
Everolimus—Muscular weakness—Carmustine—malignant glioma	0.0012	0.00377	CcSEcCtD
Everolimus—Hypokalaemia—Temozolomide—malignant glioma	0.0012	0.00376	CcSEcCtD
Everolimus—Breast disorder—Temozolomide—malignant glioma	0.00119	0.00373	CcSEcCtD
Everolimus—Aspartate aminotransferase increased—Temozolomide—malignant glioma	0.00119	0.00372	CcSEcCtD
Everolimus—Dysphagia—Carmustine—malignant glioma	0.00118	0.00369	CcSEcCtD
Everolimus—Alanine aminotransferase increased—Temozolomide—malignant glioma	0.00116	0.00364	CcSEcCtD
Everolimus—Muscular weakness—Temozolomide—malignant glioma	0.00116	0.00364	CcSEcCtD
Everolimus—Abdominal distension—Temozolomide—malignant glioma	0.00115	0.00359	CcSEcCtD
Everolimus—Dysphagia—Temozolomide—malignant glioma	0.00114	0.00357	CcSEcCtD
Everolimus—Pancytopenia—Carmustine—malignant glioma	0.00112	0.00351	CcSEcCtD
Everolimus—Neutropenia—Carmustine—malignant glioma	0.0011	0.00345	CcSEcCtD
Everolimus—Bronchitis—Temozolomide—malignant glioma	0.0011	0.00343	CcSEcCtD
Everolimus—Pancytopenia—Temozolomide—malignant glioma	0.00108	0.00339	CcSEcCtD
Everolimus—Dysuria—Temozolomide—malignant glioma	0.00107	0.00334	CcSEcCtD
Everolimus—Neutropenia—Temozolomide—malignant glioma	0.00107	0.00334	CcSEcCtD
Everolimus—Hyperglycaemia—Carmustine—malignant glioma	0.00106	0.00333	CcSEcCtD
Everolimus—Upper respiratory tract infection—Temozolomide—malignant glioma	0.00106	0.00332	CcSEcCtD
Everolimus—Pneumonia—Carmustine—malignant glioma	0.00106	0.00331	CcSEcCtD
Everolimus—Pollakiuria—Temozolomide—malignant glioma	0.00105	0.0033	CcSEcCtD
Everolimus—Erectile dysfunction—Temozolomide—malignant glioma	0.00105	0.00329	CcSEcCtD
Everolimus—Renal failure—Carmustine—malignant glioma	0.00103	0.00324	CcSEcCtD
Everolimus—Weight decreased—Temozolomide—malignant glioma	0.00103	0.00323	CcSEcCtD
Everolimus—Hyperglycaemia—Temozolomide—malignant glioma	0.00103	0.00322	CcSEcCtD
Everolimus—Stomatitis—Carmustine—malignant glioma	0.00103	0.00321	CcSEcCtD
Everolimus—Urinary tract infection—Carmustine—malignant glioma	0.00102	0.0032	CcSEcCtD
Everolimus—Pneumonia—Temozolomide—malignant glioma	0.00102	0.0032	CcSEcCtD
Everolimus—Infestation NOS—Temozolomide—malignant glioma	0.00102	0.00318	CcSEcCtD
Everolimus—Infestation—Temozolomide—malignant glioma	0.00102	0.00318	CcSEcCtD
Everolimus—Stomatitis—Temozolomide—malignant glioma	0.000991	0.0031	CcSEcCtD
Everolimus—Urinary tract infection—Temozolomide—malignant glioma	0.000988	0.00309	CcSEcCtD
Everolimus—Hepatobiliary disease—Temozolomide—malignant glioma	0.000961	0.00301	CcSEcCtD
Everolimus—Sinusitis—Temozolomide—malignant glioma	0.000953	0.00298	CcSEcCtD
Everolimus—Haemoglobin—Carmustine—malignant glioma	0.000949	0.00297	CcSEcCtD
Everolimus—Haemorrhage—Carmustine—malignant glioma	0.000944	0.00296	CcSEcCtD
Everolimus—Hallucination—Carmustine—malignant glioma	0.000939	0.00294	CcSEcCtD
Everolimus—Hypoaesthesia—Carmustine—malignant glioma	0.000939	0.00294	CcSEcCtD
Everolimus—Oedema peripheral—Carmustine—malignant glioma	0.00093	0.00291	CcSEcCtD
Everolimus—Connective tissue disorder—Carmustine—malignant glioma	0.000928	0.0029	CcSEcCtD
Everolimus—Haemoglobin—Temozolomide—malignant glioma	0.000917	0.00287	CcSEcCtD
Everolimus—Haemorrhage—Temozolomide—malignant glioma	0.000912	0.00286	CcSEcCtD
Everolimus—Hepatitis—Temozolomide—malignant glioma	0.000912	0.00286	CcSEcCtD
Everolimus—Hypoaesthesia—Temozolomide—malignant glioma	0.000908	0.00284	CcSEcCtD
Everolimus—Hallucination—Temozolomide—malignant glioma	0.000908	0.00284	CcSEcCtD
Everolimus—Pharyngitis—Temozolomide—malignant glioma	0.000905	0.00283	CcSEcCtD
Everolimus—Urinary tract disorder—Temozolomide—malignant glioma	0.000901	0.00282	CcSEcCtD
Everolimus—Oedema peripheral—Temozolomide—malignant glioma	0.000899	0.00281	CcSEcCtD
Everolimus—Connective tissue disorder—Temozolomide—malignant glioma	0.000897	0.00281	CcSEcCtD
Everolimus—Urethral disorder—Temozolomide—malignant glioma	0.000894	0.0028	CcSEcCtD
Everolimus—Eye disorder—Carmustine—malignant glioma	0.000882	0.00276	CcSEcCtD
Everolimus—Flushing—Carmustine—malignant glioma	0.000876	0.00274	CcSEcCtD
Everolimus—Eye disorder—Temozolomide—malignant glioma	0.000853	0.00267	CcSEcCtD
Everolimus—Flushing—Temozolomide—malignant glioma	0.000847	0.00265	CcSEcCtD
Everolimus—Cardiac disorder—Temozolomide—malignant glioma	0.000847	0.00265	CcSEcCtD
Everolimus—Alopecia—Carmustine—malignant glioma	0.000834	0.00261	CcSEcCtD
Everolimus—CYP3A4—central nervous system—malignant glioma	0.000832	0.0117	CbGeAlD
Everolimus—Angiopathy—Temozolomide—malignant glioma	0.000828	0.00259	CcSEcCtD
Everolimus—Mental disorder—Carmustine—malignant glioma	0.000827	0.00259	CcSEcCtD
Everolimus—Immune system disorder—Temozolomide—malignant glioma	0.000824	0.00258	CcSEcCtD
Everolimus—Mediastinal disorder—Temozolomide—malignant glioma	0.000822	0.00257	CcSEcCtD
Everolimus—Erythema—Carmustine—malignant glioma	0.000822	0.00257	CcSEcCtD
Everolimus—Malnutrition—Carmustine—malignant glioma	0.000822	0.00257	CcSEcCtD
Everolimus—Chills—Temozolomide—malignant glioma	0.000819	0.00256	CcSEcCtD
Everolimus—Alopecia—Temozolomide—malignant glioma	0.000806	0.00252	CcSEcCtD
Everolimus—Mental disorder—Temozolomide—malignant glioma	0.000799	0.0025	CcSEcCtD
Everolimus—Back pain—Carmustine—malignant glioma	0.000795	0.00249	CcSEcCtD
Everolimus—Malnutrition—Temozolomide—malignant glioma	0.000794	0.00249	CcSEcCtD
Everolimus—Erythema—Temozolomide—malignant glioma	0.000794	0.00249	CcSEcCtD
Everolimus—Dysgeusia—Temozolomide—malignant glioma	0.000778	0.00243	CcSEcCtD
Everolimus—Vision blurred—Carmustine—malignant glioma	0.000775	0.00242	CcSEcCtD
Everolimus—Tremor—Carmustine—malignant glioma	0.00077	0.00241	CcSEcCtD
Everolimus—Back pain—Temozolomide—malignant glioma	0.000768	0.00241	CcSEcCtD
Everolimus—Anaemia—Carmustine—malignant glioma	0.00076	0.00238	CcSEcCtD
Everolimus—Agitation—Carmustine—malignant glioma	0.000755	0.00236	CcSEcCtD
Everolimus—Vision blurred—Temozolomide—malignant glioma	0.000748	0.00234	CcSEcCtD
Everolimus—Tremor—Temozolomide—malignant glioma	0.000744	0.00233	CcSEcCtD
Everolimus—Ill-defined disorder—Temozolomide—malignant glioma	0.000737	0.00231	CcSEcCtD
Everolimus—Leukopenia—Carmustine—malignant glioma	0.000736	0.0023	CcSEcCtD
Everolimus—Anaemia—Temozolomide—malignant glioma	0.000734	0.0023	CcSEcCtD
Everolimus—Agitation—Temozolomide—malignant glioma	0.00073	0.00228	CcSEcCtD
Everolimus—Angioedema—Temozolomide—malignant glioma	0.000726	0.00227	CcSEcCtD
Everolimus—Malaise—Temozolomide—malignant glioma	0.000716	0.00224	CcSEcCtD
Everolimus—Convulsion—Carmustine—malignant glioma	0.000712	0.00223	CcSEcCtD
Everolimus—Leukopenia—Temozolomide—malignant glioma	0.000711	0.00223	CcSEcCtD
Everolimus—Hypertension—Carmustine—malignant glioma	0.00071	0.00222	CcSEcCtD
Everolimus—Palpitations—Temozolomide—malignant glioma	0.000702	0.0022	CcSEcCtD
Everolimus—Myalgia—Carmustine—malignant glioma	0.0007	0.00219	CcSEcCtD
Everolimus—Chest pain—Carmustine—malignant glioma	0.0007	0.00219	CcSEcCtD
Everolimus—Anxiety—Carmustine—malignant glioma	0.000697	0.00218	CcSEcCtD
Everolimus—Cough—Temozolomide—malignant glioma	0.000693	0.00217	CcSEcCtD
Everolimus—Convulsion—Temozolomide—malignant glioma	0.000688	0.00215	CcSEcCtD
Everolimus—Hypertension—Temozolomide—malignant glioma	0.000686	0.00215	CcSEcCtD
Everolimus—Myalgia—Temozolomide—malignant glioma	0.000676	0.00212	CcSEcCtD
Everolimus—Arthralgia—Temozolomide—malignant glioma	0.000676	0.00212	CcSEcCtD
Everolimus—Anxiety—Temozolomide—malignant glioma	0.000674	0.00211	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—malignant glioma	0.000671	0.0021	CcSEcCtD
Everolimus—Oedema—Carmustine—malignant glioma	0.000671	0.0021	CcSEcCtD
Everolimus—Discomfort—Temozolomide—malignant glioma	0.000668	0.00209	CcSEcCtD
Everolimus—Infection—Carmustine—malignant glioma	0.000666	0.00209	CcSEcCtD
Everolimus—Dry mouth—Temozolomide—malignant glioma	0.000661	0.00207	CcSEcCtD
Everolimus—Thrombocytopenia—Carmustine—malignant glioma	0.000657	0.00206	CcSEcCtD
Everolimus—Tachycardia—Carmustine—malignant glioma	0.000655	0.00205	CcSEcCtD
Everolimus—Oedema—Temozolomide—malignant glioma	0.000648	0.00203	CcSEcCtD
Everolimus—Infection—Temozolomide—malignant glioma	0.000644	0.00202	CcSEcCtD
Everolimus—Anorexia—Carmustine—malignant glioma	0.000639	0.002	CcSEcCtD
Everolimus—Nervous system disorder—Temozolomide—malignant glioma	0.000636	0.00199	CcSEcCtD
Everolimus—Thrombocytopenia—Temozolomide—malignant glioma	0.000635	0.00199	CcSEcCtD
Everolimus—Skin disorder—Temozolomide—malignant glioma	0.00063	0.00197	CcSEcCtD
Everolimus—Hypotension—Carmustine—malignant glioma	0.000627	0.00196	CcSEcCtD
Everolimus—Hyperhidrosis—Temozolomide—malignant glioma	0.000627	0.00196	CcSEcCtD
Everolimus—Anorexia—Temozolomide—malignant glioma	0.000618	0.00193	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Carmustine—malignant glioma	0.000611	0.00191	CcSEcCtD
Everolimus—Insomnia—Carmustine—malignant glioma	0.000607	0.0019	CcSEcCtD
Everolimus—Paraesthesia—Carmustine—malignant glioma	0.000602	0.00189	CcSEcCtD
Everolimus—Dyspnoea—Carmustine—malignant glioma	0.000598	0.00187	CcSEcCtD
Everolimus—Somnolence—Carmustine—malignant glioma	0.000596	0.00187	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Temozolomide—malignant glioma	0.000591	0.00185	CcSEcCtD
Everolimus—Insomnia—Temozolomide—malignant glioma	0.000586	0.00184	CcSEcCtD
Everolimus—Decreased appetite—Carmustine—malignant glioma	0.000583	0.00183	CcSEcCtD
Everolimus—Paraesthesia—Temozolomide—malignant glioma	0.000582	0.00182	CcSEcCtD
Everolimus—Gastrointestinal disorder—Carmustine—malignant glioma	0.000579	0.00181	CcSEcCtD
Everolimus—Dyspnoea—Temozolomide—malignant glioma	0.000578	0.00181	CcSEcCtD
Everolimus—Somnolence—Temozolomide—malignant glioma	0.000576	0.0018	CcSEcCtD
Everolimus—Constipation—Carmustine—malignant glioma	0.000574	0.0018	CcSEcCtD
Everolimus—Pain—Carmustine—malignant glioma	0.000574	0.0018	CcSEcCtD
Everolimus—Dyspepsia—Temozolomide—malignant glioma	0.000571	0.00179	CcSEcCtD
Everolimus—Decreased appetite—Temozolomide—malignant glioma	0.000563	0.00176	CcSEcCtD
Everolimus—Gastrointestinal disorder—Temozolomide—malignant glioma	0.00056	0.00175	CcSEcCtD
Everolimus—Fatigue—Temozolomide—malignant glioma	0.000559	0.00175	CcSEcCtD
Everolimus—Pain—Temozolomide—malignant glioma	0.000554	0.00174	CcSEcCtD
Everolimus—Constipation—Temozolomide—malignant glioma	0.000554	0.00174	CcSEcCtD
Everolimus—Feeling abnormal—Carmustine—malignant glioma	0.000553	0.00173	CcSEcCtD
Everolimus—Gastrointestinal pain—Carmustine—malignant glioma	0.000548	0.00172	CcSEcCtD
Everolimus—Feeling abnormal—Temozolomide—malignant glioma	0.000534	0.00167	CcSEcCtD
Everolimus—Abdominal pain—Carmustine—malignant glioma	0.00053	0.00166	CcSEcCtD
Everolimus—Body temperature increased—Carmustine—malignant glioma	0.00053	0.00166	CcSEcCtD
Everolimus—Gastrointestinal pain—Temozolomide—malignant glioma	0.00053	0.00166	CcSEcCtD
Everolimus—Abdominal pain—Temozolomide—malignant glioma	0.000512	0.0016	CcSEcCtD
Everolimus—Body temperature increased—Temozolomide—malignant glioma	0.000512	0.0016	CcSEcCtD
Everolimus—Hypersensitivity—Carmustine—malignant glioma	0.000494	0.00155	CcSEcCtD
Everolimus—Asthenia—Carmustine—malignant glioma	0.000481	0.00151	CcSEcCtD
Everolimus—Hypersensitivity—Temozolomide—malignant glioma	0.000478	0.0015	CcSEcCtD
Everolimus—Asthenia—Temozolomide—malignant glioma	0.000465	0.00146	CcSEcCtD
Everolimus—Diarrhoea—Carmustine—malignant glioma	0.000459	0.00144	CcSEcCtD
Everolimus—Pruritus—Temozolomide—malignant glioma	0.000459	0.00144	CcSEcCtD
Everolimus—Dizziness—Carmustine—malignant glioma	0.000444	0.00139	CcSEcCtD
Everolimus—Diarrhoea—Temozolomide—malignant glioma	0.000443	0.00139	CcSEcCtD
Everolimus—Dizziness—Temozolomide—malignant glioma	0.000429	0.00134	CcSEcCtD
Everolimus—Vomiting—Carmustine—malignant glioma	0.000426	0.00134	CcSEcCtD
Everolimus—Rash—Carmustine—malignant glioma	0.000423	0.00132	CcSEcCtD
Everolimus—Dermatitis—Carmustine—malignant glioma	0.000423	0.00132	CcSEcCtD
Everolimus—Headache—Carmustine—malignant glioma	0.00042	0.00132	CcSEcCtD
Everolimus—Vomiting—Temozolomide—malignant glioma	0.000412	0.00129	CcSEcCtD
Everolimus—Rash—Temozolomide—malignant glioma	0.000409	0.00128	CcSEcCtD
Everolimus—Dermatitis—Temozolomide—malignant glioma	0.000408	0.00128	CcSEcCtD
Everolimus—Headache—Temozolomide—malignant glioma	0.000406	0.00127	CcSEcCtD
Everolimus—Nausea—Carmustine—malignant glioma	0.000398	0.00125	CcSEcCtD
Everolimus—Nausea—Temozolomide—malignant glioma	0.000385	0.00121	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—HEY1—malignant glioma	7.96e-05	0.000197	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—PTPN11—malignant glioma	7.95e-05	0.000197	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—AKT1—malignant glioma	7.94e-05	0.000197	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—AKT1—malignant glioma	7.94e-05	0.000197	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—AKT1—malignant glioma	7.94e-05	0.000197	CbGpPWpGaD
Everolimus—FKBP1A—Disease—NOTCH1—malignant glioma	7.91e-05	0.000196	CbGpPWpGaD
Everolimus—MTOR—Disease—FBXW7—malignant glioma	7.88e-05	0.000195	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—AKT1—malignant glioma	7.87e-05	0.000195	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—AKT1—malignant glioma	7.8e-05	0.000193	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—CD80—malignant glioma	7.78e-05	0.000193	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—AKT1—malignant glioma	7.77e-05	0.000192	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MMP3—malignant glioma	7.76e-05	0.000192	CbGpPWpGaD
Everolimus—FKBP1A—Disease—CD80—malignant glioma	7.75e-05	0.000192	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—HIST1H3B—malignant glioma	7.74e-05	0.000191	CbGpPWpGaD
Everolimus—FKBP1A—Disease—APC—malignant glioma	7.73e-05	0.000191	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CDKN2B—malignant glioma	7.69e-05	0.00019	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—EGF—malignant glioma	7.68e-05	0.00019	CbGpPWpGaD
Everolimus—FKBP1A—Disease—EGF—malignant glioma	7.65e-05	0.000189	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—EGFR—malignant glioma	7.63e-05	0.000189	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—PTPN11—malignant glioma	7.63e-05	0.000189	CbGpPWpGaD
Everolimus—FKBP1A—Disease—PTPN11—malignant glioma	7.6e-05	0.000188	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PTK2—malignant glioma	7.47e-05	0.000185	CbGpPWpGaD
Everolimus—MTOR—Immune System—IFNA2—malignant glioma	7.46e-05	0.000185	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—AKT2—malignant glioma	7.4e-05	0.000183	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—AKT1—malignant glioma	7.35e-05	0.000182	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—HES1—malignant glioma	7.34e-05	0.000182	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—NCOR1—malignant glioma	7.29e-05	0.00018	CbGpPWpGaD
Everolimus—FKBP1A—Disease—BRAF—malignant glioma	7.27e-05	0.00018	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—KRAS—malignant glioma	7.21e-05	0.000178	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—PIK3CD—malignant glioma	7.11e-05	0.000176	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—AKT2—malignant glioma	7.11e-05	0.000176	CbGpPWpGaD
Everolimus—FKBP1A—Disease—AKT2—malignant glioma	7.08e-05	0.000175	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—JAG2—malignant glioma	7.06e-05	0.000175	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—AKT1—malignant glioma	7.04e-05	0.000174	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PDGFRA—malignant glioma	6.99e-05	0.000173	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—TP53—malignant glioma	6.83e-05	0.000169	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—PIK3CD—malignant glioma	6.83e-05	0.000169	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—FGF2—malignant glioma	6.81e-05	0.000168	CbGpPWpGaD
Everolimus—FKBP1A—Disease—PIK3CD—malignant glioma	6.8e-05	0.000168	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—SPP1—malignant glioma	6.78e-05	0.000168	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—PIK3CA—malignant glioma	6.62e-05	0.000164	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—FGF2—malignant glioma	6.54e-05	0.000162	CbGpPWpGaD
Everolimus—FKBP1A—Disease—FGF2—malignant glioma	6.51e-05	0.000161	CbGpPWpGaD
Everolimus—MTOR—Immune System—PTK2—malignant glioma	6.5e-05	0.000161	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—BCL2—malignant glioma	6.47e-05	0.00016	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—TERT—malignant glioma	6.43e-05	0.000159	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—MDM2—malignant glioma	6.37e-05	0.000158	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—RAF1—malignant glioma	6.35e-05	0.000157	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—ERBB2—malignant glioma	6.28e-05	0.000155	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PDGFB—malignant glioma	6.27e-05	0.000155	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—FGFR1—malignant glioma	6.24e-05	0.000154	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—PIK3CB—malignant glioma	6.2e-05	0.000153	CbGpPWpGaD
Everolimus—MTOR—Disease—CDKN2B—malignant glioma	6.18e-05	0.000153	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—HIF1A—malignant glioma	6.15e-05	0.000152	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—MDM2—malignant glioma	6.12e-05	0.000151	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—RAF1—malignant glioma	6.1e-05	0.000151	CbGpPWpGaD
Everolimus—FKBP1A—Disease—MDM2—malignant glioma	6.09e-05	0.000151	CbGpPWpGaD
Everolimus—MTOR—Immune System—PDGFRA—malignant glioma	6.08e-05	0.00015	CbGpPWpGaD
Everolimus—FKBP1A—Disease—RAF1—malignant glioma	6.07e-05	0.00015	CbGpPWpGaD
Everolimus—MTOR—Immune System—HLA-B—malignant glioma	6.04e-05	0.000149	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—ERBB2—malignant glioma	6.03e-05	0.000149	CbGpPWpGaD
Everolimus—FKBP1A—Disease—ERBB2—malignant glioma	6.01e-05	0.000149	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—H3F3A—malignant glioma	5.98e-05	0.000148	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—PIK3CB—malignant glioma	5.95e-05	0.000147	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CAV1—malignant glioma	5.95e-05	0.000147	CbGpPWpGaD
Everolimus—FKBP1A—Disease—PIK3CB—malignant glioma	5.93e-05	0.000147	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CXCR3—malignant glioma	5.92e-05	0.000146	CbGpPWpGaD
Everolimus—MTOR—Disease—HES1—malignant glioma	5.89e-05	0.000146	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—KDR—malignant glioma	5.88e-05	0.000145	CbGpPWpGaD
Everolimus—FKBP1A—Disease—PTGS2—malignant glioma	5.87e-05	0.000145	CbGpPWpGaD
Everolimus—MTOR—Disease—NCOR1—malignant glioma	5.86e-05	0.000145	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NTRK2—malignant glioma	5.76e-05	0.000142	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—YWHAE—malignant glioma	5.76e-05	0.000142	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—FLT1—malignant glioma	5.73e-05	0.000142	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—DUSP6—malignant glioma	5.71e-05	0.000141	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—F2—malignant glioma	5.66e-05	0.00014	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—FN1—malignant glioma	5.66e-05	0.00014	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—JAG1—malignant glioma	5.63e-05	0.000139	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NOTCH3—malignant glioma	5.61e-05	0.000139	CbGpPWpGaD
Everolimus—MTOR—Disease—PDGFRA—malignant glioma	5.61e-05	0.000139	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—BAD—malignant glioma	5.59e-05	0.000138	CbGpPWpGaD
Everolimus—MTOR—Immune System—HLA-A—malignant glioma	5.59e-05	0.000138	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—NOTCH1—malignant glioma	5.54e-05	0.000137	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—FBXW7—malignant glioma	5.52e-05	0.000137	CbGpPWpGaD
Everolimus—MTOR—Immune System—PDGFB—malignant glioma	5.46e-05	0.000135	CbGpPWpGaD
Everolimus—MTOR—Immune System—FGFR1—malignant glioma	5.43e-05	0.000134	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CD80—malignant glioma	5.43e-05	0.000134	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—APC—malignant glioma	5.42e-05	0.000134	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PIK3CG—malignant glioma	5.42e-05	0.000134	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—BDKRB2—malignant glioma	5.41e-05	0.000134	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—AKT1—malignant glioma	5.41e-05	0.000134	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—PTEN—malignant glioma	5.36e-05	0.000133	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—EGF—malignant glioma	5.35e-05	0.000132	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PTPN11—malignant glioma	5.32e-05	0.000132	CbGpPWpGaD
Everolimus—MTOR—Disease—HLA-A—malignant glioma	5.16e-05	0.000128	CbGpPWpGaD
Everolimus—MTOR—Disease—TERT—malignant glioma	5.16e-05	0.000128	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—PTEN—malignant glioma	5.14e-05	0.000127	CbGpPWpGaD
Everolimus—FKBP1A—Disease—PTEN—malignant glioma	5.12e-05	0.000127	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—BRAF—malignant glioma	5.09e-05	0.000126	CbGpPWpGaD
Everolimus—MTOR—Disease—PDGFB—malignant glioma	5.04e-05	0.000125	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NOTCH2—malignant glioma	5.03e-05	0.000125	CbGpPWpGaD
Everolimus—MTOR—Disease—FGFR1—malignant glioma	5.01e-05	0.000124	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—AKT2—malignant glioma	4.96e-05	0.000123	CbGpPWpGaD
Everolimus—MTOR—Disease—HIF1A—malignant glioma	4.94e-05	0.000122	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—KNG1—malignant glioma	4.92e-05	0.000122	CbGpPWpGaD
Everolimus—MTOR—Immune System—BAD—malignant glioma	4.86e-05	0.00012	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—COX8A—malignant glioma	4.81e-05	0.000119	CbGpPWpGaD
Everolimus—MTOR—Disease—CAV1—malignant glioma	4.78e-05	0.000118	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PIK3CD—malignant glioma	4.76e-05	0.000118	CbGpPWpGaD
Everolimus—MTOR—Immune System—CD80—malignant glioma	4.72e-05	0.000117	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NTRK1—malignant glioma	4.69e-05	0.000116	CbGpPWpGaD
Everolimus—MTOR—Immune System—EGF—malignant glioma	4.66e-05	0.000115	CbGpPWpGaD
Everolimus—MTOR—Immune System—PTPN11—malignant glioma	4.63e-05	0.000115	CbGpPWpGaD
Everolimus—FKBP1A—Disease—STAT3—malignant glioma	4.58e-05	0.000113	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—FGF2—malignant glioma	4.56e-05	0.000113	CbGpPWpGaD
Everolimus—MTOR—Disease—BAD—malignant glioma	4.49e-05	0.000111	CbGpPWpGaD
Everolimus—MTOR—Disease—NOTCH1—malignant glioma	4.45e-05	0.00011	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MMP3—malignant glioma	4.36e-05	0.000108	CbGpPWpGaD
Everolimus—MTOR—Disease—CD80—malignant glioma	4.36e-05	0.000108	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—EGFR—malignant glioma	4.35e-05	0.000108	CbGpPWpGaD
Everolimus—MTOR—Disease—APC—malignant glioma	4.35e-05	0.000108	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CDKN2B—malignant glioma	4.33e-05	0.000107	CbGpPWpGaD
Everolimus—MTOR—Immune System—AKT2—malignant glioma	4.31e-05	0.000107	CbGpPWpGaD
Everolimus—MTOR—Disease—EGF—malignant glioma	4.3e-05	0.000106	CbGpPWpGaD
Everolimus—MTOR—Disease—PTPN11—malignant glioma	4.27e-05	0.000106	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MDM2—malignant glioma	4.27e-05	0.000106	CbGpPWpGaD
Everolimus—FKBP1A—Disease—MYC—malignant glioma	4.26e-05	0.000105	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—RAF1—malignant glioma	4.25e-05	0.000105	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—ERBB2—malignant glioma	4.21e-05	0.000104	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PTK2—malignant glioma	4.2e-05	0.000104	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—EGFR—malignant glioma	4.18e-05	0.000103	CbGpPWpGaD
Everolimus—FKBP1A—Disease—EGFR—malignant glioma	4.16e-05	0.000103	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PIK3CB—malignant glioma	4.15e-05	0.000103	CbGpPWpGaD
Everolimus—MTOR—Immune System—PIK3CD—malignant glioma	4.14e-05	0.000102	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—HES1—malignant glioma	4.13e-05	0.000102	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—KRAS—malignant glioma	4.11e-05	0.000102	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NCOR1—malignant glioma	4.1e-05	0.000102	CbGpPWpGaD
Everolimus—MTOR—Disease—BRAF—malignant glioma	4.09e-05	0.000101	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ASMT—malignant glioma	4.09e-05	0.000101	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CXCL8—malignant glioma	3.99e-05	9.87e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—AKT2—malignant glioma	3.98e-05	9.85e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—FGF2—malignant glioma	3.97e-05	9.81e-05	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—KRAS—malignant glioma	3.95e-05	9.77e-05	CbGpPWpGaD
Everolimus—FKBP1A—Disease—KRAS—malignant glioma	3.93e-05	9.73e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PDGFRA—malignant glioma	3.93e-05	9.72e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—BCAN—malignant glioma	3.84e-05	9.51e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—PIK3CD—malignant glioma	3.82e-05	9.46e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CASP3—malignant glioma	3.82e-05	9.45e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—SPP1—malignant glioma	3.81e-05	9.44e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IL2—malignant glioma	3.81e-05	9.43e-05	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—PIK3CA—malignant glioma	3.78e-05	9.35e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—BCL2—malignant glioma	3.77e-05	9.32e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—IFNG—malignant glioma	3.73e-05	9.23e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—MDM2—malignant glioma	3.71e-05	9.18e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—RAF1—malignant glioma	3.7e-05	9.15e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—FGF2—malignant glioma	3.66e-05	9.06e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—ERBB2—malignant glioma	3.66e-05	9.05e-05	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—PIK3CA—malignant glioma	3.63e-05	8.98e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TERT—malignant glioma	3.62e-05	8.95e-05	CbGpPWpGaD
Everolimus—FKBP1A—Disease—PIK3CA—malignant glioma	3.61e-05	8.94e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—PIK3CB—malignant glioma	3.61e-05	8.93e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MMP9—malignant glioma	3.61e-05	8.93e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PTEN—malignant glioma	3.59e-05	8.87e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PDGFB—malignant glioma	3.53e-05	8.73e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—FGFR1—malignant glioma	3.51e-05	8.69e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—HIF1A—malignant glioma	3.46e-05	8.56e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—MDM2—malignant glioma	3.43e-05	8.48e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—RAF1—malignant glioma	3.41e-05	8.45e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—ERBB2—malignant glioma	3.38e-05	8.36e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CAV1—malignant glioma	3.34e-05	8.27e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—PIK3CB—malignant glioma	3.33e-05	8.25e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL1B—malignant glioma	3.33e-05	8.23e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL2—malignant glioma	3.32e-05	8.2e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—KDR—malignant glioma	3.31e-05	8.18e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—PTGS2—malignant glioma	3.3e-05	8.17e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—VEGFA—malignant glioma	3.24e-05	8.02e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—STAT3—malignant glioma	3.21e-05	7.94e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—F2—malignant glioma	3.18e-05	7.88e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—FN1—malignant glioma	3.18e-05	7.88e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—BAD—malignant glioma	3.15e-05	7.78e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—PTEN—malignant glioma	3.12e-05	7.72e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NOTCH1—malignant glioma	3.11e-05	7.71e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—IDH2—malignant glioma	3.1e-05	7.67e-05	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—AKT1—malignant glioma	3.09e-05	7.64e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CD80—malignant glioma	3.05e-05	7.55e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—APC—malignant glioma	3.05e-05	7.54e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PIK3CG—malignant glioma	3.05e-05	7.54e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—EGF—malignant glioma	3.01e-05	7.45e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PTPN11—malignant glioma	2.99e-05	7.41e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MYC—malignant glioma	2.98e-05	7.37e-05	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—AKT1—malignant glioma	2.96e-05	7.33e-05	CbGpPWpGaD
Everolimus—FKBP1A—Disease—AKT1—malignant glioma	2.95e-05	7.3e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—EGFR—malignant glioma	2.92e-05	7.21e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CYP2B6—malignant glioma	2.91e-05	7.21e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—PTEN—malignant glioma	2.88e-05	7.13e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—BRAF—malignant glioma	2.86e-05	7.08e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—STAT3—malignant glioma	2.79e-05	6.9e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—AKT2—malignant glioma	2.79e-05	6.9e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—KRAS—malignant glioma	2.75e-05	6.81e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PIK3CD—malignant glioma	2.68e-05	6.63e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—IDH1—malignant glioma	2.66e-05	6.59e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—SPHK1—malignant glioma	2.58e-05	6.38e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—STAT3—malignant glioma	2.58e-05	6.37e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—FGF2—malignant glioma	2.56e-05	6.34e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—EGFR—malignant glioma	2.54e-05	6.27e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PIK3CA—malignant glioma	2.53e-05	6.26e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CYP2C18—malignant glioma	2.53e-05	6.25e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—TP53—malignant glioma	2.45e-05	6.06e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MDM2—malignant glioma	2.4e-05	5.94e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—KRAS—malignant glioma	2.4e-05	5.93e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—MYC—malignant glioma	2.39e-05	5.92e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—RAF1—malignant glioma	2.39e-05	5.92e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—ERBB2—malignant glioma	2.37e-05	5.85e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—EGFR—malignant glioma	2.34e-05	5.79e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PIK3CB—malignant glioma	2.33e-05	5.78e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CXCL8—malignant glioma	2.24e-05	5.55e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—KRAS—malignant glioma	2.21e-05	5.47e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—PIK3CA—malignant glioma	2.2e-05	5.45e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CASP3—malignant glioma	2.15e-05	5.31e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IL2—malignant glioma	2.14e-05	5.3e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—AKT1—malignant glioma	2.07e-05	5.11e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GSTT1—malignant glioma	2.04e-05	5.06e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—PIK3CA—malignant glioma	2.03e-05	5.03e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MMP9—malignant glioma	2.03e-05	5.02e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PTEN—malignant glioma	2.02e-05	4.99e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PTGS1—malignant glioma	1.91e-05	4.74e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—VEGFA—malignant glioma	1.82e-05	4.51e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—STAT3—malignant glioma	1.8e-05	4.46e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—AKT1—malignant glioma	1.8e-05	4.45e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—BCHE—malignant glioma	1.78e-05	4.4e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—SLC5A5—malignant glioma	1.76e-05	4.35e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MYC—malignant glioma	1.68e-05	4.15e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—AKT1—malignant glioma	1.66e-05	4.11e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—EGFR—malignant glioma	1.64e-05	4.06e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—KRAS—malignant glioma	1.55e-05	3.83e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PIK3CA—malignant glioma	1.42e-05	3.52e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GSTP1—malignant glioma	1.42e-05	3.5e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CAT—malignant glioma	1.38e-05	3.41e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TP53—malignant glioma	1.38e-05	3.41e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—NCOR1—malignant glioma	1.3e-05	3.22e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—AKT1—malignant glioma	1.16e-05	2.88e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CAV1—malignant glioma	1.06e-05	2.62e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PIK3CG—malignant glioma	9.66e-06	2.39e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PPARG—malignant glioma	9.33e-06	2.31e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PIK3CD—malignant glioma	8.49e-06	2.1e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PIK3CB—malignant glioma	7.4e-06	1.83e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PTGS2—malignant glioma	7.34e-06	1.82e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PTEN—malignant glioma	6.4e-06	1.58e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PIK3CA—malignant glioma	4.51e-06	1.12e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—AKT1—malignant glioma	3.69e-06	9.12e-06	CbGpPWpGaD
